Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
1.090
-0.240 (-18.05%)
At close: Jan 31, 2025, 4:00 PM
1.280
+0.190 (17.43%)
After-hours: Jan 31, 2025, 7:57 PM EST
Akari Therapeutics, Employees
As of December 31, 2023, Akari Therapeutics, had 12 total employees, including 9 full-time and 3 part-time employees. The number of employees decreased by 3 or -20.00% compared to the previous year.
Employees
12
Change (1Y)
-3
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$1,679,750
Market Cap
26.99M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
AKTX News
- 6 weeks ago - Akari Therapeutics Announces Key Leadership Appointments - GlobeNewsWire
- 6 weeks ago - Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - GlobeNewsWire
- 3 months ago - Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger - GlobeNewsWire
- 5 months ago - Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights - GlobeNewsWire
- 5 months ago - Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy - GlobeNewsWire
- 9 months ago - Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights - GlobeNewsWire
- 9 months ago - Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics - GlobeNewsWire